Department of Dermatology, Kangnam Sacred Heart Hospital, Hallym University, 1 Singil-ro, Seoul 07441, Korea.
Department of Microbiology, School of Medicine, Ewha Womans University, 911-1 Mok-Dong, Yang Cheon-Gu, Seoul 158-710, Korea.
Int J Mol Sci. 2017 Nov 15;18(11):2425. doi: 10.3390/ijms18112425.
Post-burn pruritus is a common and distressing sequela of burn scars. Empirical antipruritic treatments usually fail to have a satisfactory outcome because of their limited selectivity and possible side effects. Therefore, novel drug targets need to be identified. Here, we aimed to investigate the possible role of protease-activated receptor 2 (PAR2) and transient receptor potential vanniloid 3 (TRPV3), along with the relation of TRPV3 to thymic stromal lymphopoietin (TSLP). Specimens from normal (unscarred) or burn-scarred (with or without pruritus) tissue were obtained from burn patients for this study. In each sample, the keratinocytes were isolated and cultured, and the intracellular Ca level at the time of stimulation of each factor was quantified and the interaction was screened. PAR2 function was reduced by antagonism of TRPV3. Inhibiting protein kinase A (PKA) and protein kinase C (PKC) reduced TRPV3 function. TSLP mRNA and protein, and TSLPR protein expressions, increased in scars with post-burn pruritus, compared to scars without it or to normal tissues. In addition, TRPV1 or TRPV3 activation induced increased TSLP expression. Conclusively, TRPV3 may contribute to pruritus in burn scars through TSLP, and can be considered a potential therapeutic target for post-burn pruritus.
烧伤后瘙痒是烧伤瘢痕的一种常见且令人痛苦的后遗症。由于经验性止痒治疗的选择性有限且可能有副作用,因此通常无法获得满意的效果。因此,需要确定新的药物靶点。在这里,我们旨在研究蛋白酶激活受体 2(PAR2)和瞬时受体电位香草酸 3(TRPV3)的可能作用,以及 TRPV3 与胸腺基质淋巴细胞生成素(TSLP)的关系。为此研究,从烧伤患者的正常(无瘢痕)或烧伤瘢痕(有或无瘙痒)组织中获得标本。在每个样本中,分离并培养角质形成细胞,并定量刺激每个因素时的细胞内 Ca 水平,并筛选相互作用。TRPV3 的功能通过 TRPV3 的拮抗作用而降低。抑制蛋白激酶 A(PKA)和蛋白激酶 C(PKC)降低了 TRPV3 的功能。与无瘙痒性瘢痕或正常组织相比,瘙痒性烧伤瘢痕中 TSLP mRNA 和蛋白以及 TSLPR 蛋白表达增加。此外,TRPV1 或 TRPV3 的激活诱导 TSLP 表达增加。总之,TRPV3 通过 TSLP 可能有助于烧伤瘢痕的瘙痒,可被视为治疗烧伤后瘙痒的潜在治疗靶点。